Northwest Biotherapeutics (NWBO) initiates a DCVax Phase 3 clinical trial at a medical center in Dresden, Germany. Three more sites will come on line in June followed by four more in July. The Dresden site has begun screening patients for enrollment. The initiation process will take ~six months per site according to the company.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs